AZD1222疫苗接种后血栓性血小板减少综合征风险:欧洲VAC4EU上市后安全性研究
本研究基于欧洲多国数据库开展AZD1222疫苗上市后安全性研究,评估血栓性血小板减少综合征(TTS)风险。结果显示,与同期未接种者、历史对照或mRNA疫苗接种者相比,AZD1222接种后TTS风险可能略有增加,尤其在<60岁人群和首次接种后1-42天,但总体证据受潜在偏倚影响。
要点
- AZD1222接种后TTS风险可能轻度升高,尤其在<60岁人群和首次接种后1-42天。
- 与历史对照的荟萃分析IRR为1.78(95%CI 1.12-2.82),与mRNA疫苗对照IRR为1.12(95%CI 0.61-2.05)。
- 经病例验证后阳性预测值调整的IRR均<1,提示潜在偏倚影响结果解读。
核心结论
- 综合证据提示AZD1222接种后TTS风险可能增加,尤其在<60岁人群和首次接种后1-42天,与文献一致。
研究设计与样本
- 基于CPRD Aurum(英国)、VID(西班牙)、SIDIAP(西班牙)和PHARMO-GP(荷兰)数据库的队列研究。
- AZD1222接种者按年龄、性别、地区、既往COVID-19和特殊人群状态匹配同期未接种、历史或mRNA疫苗接种对照。
- 匹配同期未接种对照5,321,930人,历史对照4,831,010人,mRNA主动对照4,028,091人(仅CPRD)。
主要发现
- 倾向评分加权IRR(95%CI)为CPRD 1.14(0.60-2.17)、VID 0.34(0.10-1.18)、SIDIAP 0.66(0.33-1.34),PHARMO为零事件。
- 在<60岁人群或较短风险窗内,AZD1222接种者TTS的IR和IRR较同期未接种者更高。
- 经病例验证后阳性预测值调整的IRR均<1。
- 与历史对照的荟萃分析IRR为1.78(95%CI 1.12-2.82;I2=0%)。
- 与mRNA主动对照的IRR为1.12(95%CI 0.61-2.05)。
关键数值与推荐
- 事件定义为±10天内发生血栓栓塞事件和血小板减少,且前一年无TTS。
- CPRD中83%受种者于2021年第一季度接种,64%<60岁;VID、SIDIAP和PHARMO中>59%在2021年第一季度后接种,多数≥60岁。
临床怎么用
- 监测AZD1222接种后TTS事件,尤其关注<60岁人群和首次接种后1-42天。
- 解读不同数据源IRR差异时需考虑年龄分布差异及风险最小化措施的影响。
局限性
- 存在信息性删失导致的选择偏倚和潜在结局错分。
- 各国风险最小化措施不同导致年龄分布差异,可能解释IRR差异。
- 部分数据库事件数少或为零,限制精确估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A post-authorisation safety study was conducted for the AZD1222 COVID-19 vaccine. This paper presents one study outcome, thrombosis with thrombocytopenia syndrome (TTS), and estimates TTS risk in subjects administered ≥1 AZD1222 dose versus concurrent unvaccinated, pre-pandemic historical, or mRNA-vaccinated subjects. The cohort study used data from CPRD Aurum (UK), VID (Spain), SIDIAP (Spain) and PHARMO-GP database (PHARMO) (the Netherlands). AZD1222-vaccinated subjects were matched on age, sex, region, prior COVID-19, and special population status. Incident venous TTS was defined as a thromboembolic event and thrombocytopaenia within ±10 days and no TTS within the prior year. 5,321,930 subjects were matched with concurrent unvaccinated comparators, 4,831,010 with historical comparators, and 4,028,091 with mRNA active comparators (CPRD only). In CPRD, 83% of subjects were vaccinated in Q1 2021; 64% were < 60 years. In VID, SIDIAP, and PHARMO, >59% were vaccinated after Q1 2021; most subjects were ≥ 60 years. Propensity score-weighted incidence rate ratios (IRRs) (95% confidence intervals) for TTS were CPRD, 1.14 (0.60-2.17); VID, 0.34 (0.10-1.18); SIDIAP, 0.66 (0.33-1.34); and zero events in PHARMO. Incidence rates (IRs) and IRRs for TTS, where available, were higher in AZD1222-vaccinated versus concurrent unvaccinated subjects <60 years or during shorter risk windows. After case validation, positive predictive value-adjusted IRRs were < 1. For historical comparators, meta-analysis resulted in an IRR of 1.78 (95% CI,1.12-2.82; I2 = 0%). For mRNA active comparators, the IRR was 1.12 (95% CI,0.61-2.05). Considering the magnitude, precision, and potential biases-such as selection bias due to informative censoring and potential outcome misclassification-the totality of evidence suggests a possible increased risk of TTS with post-AZD1222 vaccination that may be higher among subjects <60 years and 1-42 days after first AZD1222 dose, in line with the literature. Differential age distributions resulting from country-level differences in the risk minimisation measures may explain IRR disparities across data sources.
引用
- Forns J, Pajouheshnia R, Aurelius T, et al. Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study. Vaccine. 2026. PMID: 42161097. doi:10.1016/j.vaccine.2026.128723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。